Azathioprine-reduced Bcl-2 synthesis and release could lead to mitochondrial dysfunction and cell death, as suggested an effective treatment for NMO (Menor et al., 2004; Papadopoulos et al., 2014). Here, BCL2 is linked to neuromyelitis optica.